Association of cytochrome P450 2C19* 2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents

IY Oh, KW Park, SH Kang, JJ Park, SH Na, HJ Kang… - Heart, 2012 - heart.bmj.com
Background Although East Asians carry the cytochrome P450 (CYP) 2C19* 2 allele more
frequently than do Caucasians, the impact of the CYP2C19* 2 allele on clopidogrel …

Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel

R Nishio, T Shinke, H Otake, T Sawada… - Circulation …, 2012 - jstage.jst.go.jp
Background: Cytochrome P450 (CYP) 2C19 polymorphism is associated with reduced
responsiveness to clopidogrel and poor clinical outcome after drug-eluting stent (DES) …

Impact of cytochrome P450 2C19* 2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel

T Sawada, T Shinke, J Shite, T Honjo… - Circulation …, 2011 - jstage.jst.go.jp
Background: The cytochrome P450 (CYP) 2C19* 2 polymorphism is associated with
reduced responsiveness to clopidogrel and poor clinical outcome after stent implantation …

CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis

Z Xi, F Fang, J Wang, J AlHelal, Y Zhou, W Liu - Platelets, 2019 - Taylor & Francis
The effect of CYP2C19 gene polymorphism on clinical outcomes of patients with coronary
artery disease (CAD) treated with clopidogrel remains controversial. Ethnicity has been …

Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention

SH Lee, YH Jeong, D Hong, KH Choi, JM Lee… - Cardiovascular …, 2023 - jacc.org
Background Although there is a growing body of evidence that CYP2C19 genotyping can be
beneficial when considering treatment with clopidogrel after percutaneous coronary …

Cytochrome P450 2C19* 2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

F Sofi, B Giusti, R Marcucci, AM Gori… - The …, 2011 - nature.com
Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary …

Z Zhong, J Hou, Q Zhang, B Li, C Li, Z Liu… - European Journal of …, 2018 - Springer
Background and objectives The objective of this study is to evaluate the effects of
cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events …

Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent …

T Nakata, M Miyahara, K Nakatani, H Wada… - Circulation …, 2013 - jstage.jst.go.jp
Background: CYP2C19 loss-of-function genotype (* 2 and/or* 3 alleles) is related to low
responsiveness to clopidogrel, which is a risk factor for ischemic cardiac events. The …

Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous …

JJ Zou, HG Xie, SL Chen, J Tan, L Lin, YY Zhao… - European journal of …, 2013 - Springer
Background and objectives A large number of clinical studies have well demonstrated that
the loss-of-function variant allele CYP2C19* 2 is associated with attenuated response to …

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

JW Suh, BK Koo, SY Zhang, KW Park, JY Cho, IJ Jang… - Cmaj, 2006 - Can Med Assoc
Background: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A
(CYP3A) isoenzymes, including CYP3A5, in order to be active. It is controversial whether …